brca2 mutation prostate cancer

brca2 mutation prostate cancer

BRCA2 Prostate Cancer vs Traditional Treatment Hidden Risks?

A BRCA2 mutation adds hidden risks to prostate cancer treatment, making standard approaches less predictable and requiring tailored surveillance and therapies. A 45% response rate for olaparib in BRCA2-mutated prostate cancer has reshaped treatment expectations. I first heard the figure while reviewing a Medscape briefing on PARP inhibitors, and it